Maharashtra’s Food and Drug Administration (FDA) cancels the drug sale licences of Cipla’s Pune facility, according to multiple reports. The FDA order follows findings from an investigation and subsequent inspections, which cite problems related to drug packaging, recall processes, and compliance in the facility.
Reported issues include alleged mislabelling on prescription drugs, which officials say could encourage self-medication, along with deficiencies in storage arrangements and gaps in warehouse record-keeping. The company is contesting the FDA’s decision, arguing against the basis of the cancellation.
Across the coverage, the core focus is the same: the state FDA withdraws Cipla Pune’s sale licences after inspection findings. However, outlets differ in emphasis on the seriousness and implications of the alleged lapses. Business Line notes Cipla’s position that the order does not allege concerns about product safety, quality, or efficacy, nor does it identify any patient safety issue, while other reports focus more directly on the specific compliance and labelling concerns raised by regulators.
